Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors

Phase 2 Active not recruiting 184 enrolled SOLTI Breast Cancer Research Group Novartis · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label, parallel group, non-randomized, multicenter phase II study to evaluate the efficacy of spartalizumab (cohorts 1 and 2) and tislelizumab (cohort 3) in monotherapy in patients with PD1-high-expressing tumors.

Timeline

Start: 2021-04-12
Primary completion: 2025-09-30
Completion: 2027-03-31

Publications

Prat A, Paz-Ares L, Juan M, Felip E, Garralda E, Gonzalez B, Arance A, Martin-Liberal J, Gavila J, Lopez-Gonzalez A, Cejalvo JM, Izarzugaza Y, Amillano K, Corbacho JG, Saura C, Racca F, Hierro C, Sanfeliu E, Gonzalez X, Canes J, Villacampa G, Salvador F, Pascual T, Mesia R, Cervantes A, Tabernero J. SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA. Future Oncol. 2022 Oct 6. doi: 10.2217/fon-2022-0660. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Spartalizumab	Monoclonal antibody	400 mg	Intravenous
Subject	Tislelizumab	Monoclonal antibody	300 mg	Intravenous

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors

Summary

Timeline

Publications

Drugs

Indications